Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tiotropium + olodaterol fixed-dose combination versus tiotropium and placebo in COPD (12-week study 1237.25)
NL-OMON38556Phase 3Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tiotropium and olodaterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: FEV1 AUC0-3h response, Trough FEV1 response and 1 more. Planned start Sep 2013; status: withdrawn.
02
Drugs
tiotropiumolodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON38556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38556.